Literature DB >> 29246616

NEDA treatment target? No evident disease activity as an actionable outcome in practice.

Natalie E Parks1, Eoin P Flanagan2, Claudia F Lucchinetti3, Dean M Wingerchuk4.   

Abstract

"No evident disease activity" (NEDA) is a proposed measure of disease activity-free status in multiple sclerosis (MS) that is typically defined as absence of relapses, disability progression, and MRI activity over a defined time period. NEDA is increasingly reported in randomized controlled trials of MS disease modifying therapies where it has some perceived advantages over outcomes such as annualized relapse rate. NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable treatment target in clinical practice.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Disease modifying therapy; Multiple sclerosis; No evident disease activity; Outcome measures; Treatment target

Mesh:

Year:  2017        PMID: 29246616     DOI: 10.1016/j.jns.2017.10.015

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

Review 1.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

2.  Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.

Authors:  Dimitrios Papadopoulos; Dimos-Dimitrios D Mitsikostas
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

3.  The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.

Authors:  Elena Di Sabatino; Lorenzo Gaetani; Silvia Sperandei; Andrea Fiacca; Giorgio Guercini; Lucilla Parnetti; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2021-11-24       Impact factor: 4.849

Review 4.  Multiple Sclerosis: Systemic Challenges to Cost-Effective Care.

Authors:  David R Weinstein; Gary M Owens; Ankit Gandhi
Journal:  Am Health Drug Benefits       Date:  2022-03

5.  Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.

Authors:  Jessica Frau; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Luigina Musu; Eleonora Cocco
Journal:  J Neurol       Date:  2019-03-12       Impact factor: 4.849

6.  Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis.

Authors:  Ofir Zmira; Alex I Halpern; Lital Abraham; Anat Achiron
Journal:  Acta Neurol Belg       Date:  2020-05-23       Impact factor: 2.396

7.  Population-based study of "no evident disease activity" in MS.

Authors:  Natalie E Parks; Sean J Pittock; Jay Mandrekar; Orhun H Kantarci; Claudia F Lucchinetti; Brian G Weinshenker; B Mark Keegan; W Oliver Tobin; Jan-Mendelt Tillema; Michel Toledano; Eoin P Flanagan
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-08-16

8.  Sema4A is implicated in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase.

Authors:  Toru Koda; Akiko Namba; Makoto Kinoshita; Yuji Nakatsuji; Tomoyuki Sugimoto; Kaori Sakakibara; Satoru Tada; Mikito Shimizu; Kazuya Yamashita; Kazushiro Takata; Teruyuki Ishikura; Syo Murata; Shohei Beppu; Atsushi Kumanogoh; Hideki Mochizuki; Tatsusada Okuno
Journal:  J Neuroinflammation       Date:  2020-03-13       Impact factor: 8.322

Review 9.  Comprehensive Assessment of Multiple Sclerosis: From Immunotherapy and Immunopathogenesis to Predictive Biomarkers.

Authors:  Soheil Vazifedoust; Hadi Esmaeili Gouvarchin Ghaleh; Mostafa Khafaei; Fateme Azemati; Bahman Jalali Kondori
Journal:  Iran J Pathol       Date:  2022-08-11

Review 10.  Advances in the Treatment of Multiple Sclerosis.

Authors:  Carolyn Goldschmidt; Marisa P McGinley
Journal:  Neurol Clin       Date:  2020-11-07       Impact factor: 3.806

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.